Diffuse large B-cell lymphoma trials in South Korea
18 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Where
- Busan, Daejeon, Goyang-si, Seoul
- Age
- 18 years and over
- People
- 1,046 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06717347 · EU 2024-515566-13-00 - Phase 2Taking peopleEvaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Where
- Seongnam-si, Seoul
- Age
- 18 years and over
- People
- 130 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06806033 · EU 2024-516791-15-00 - Phase 3Taking peopleA Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Where
- Busan, Daegu, Incheon, Seoul, Suwon
- Age
- 18 years and over
- People
- 904 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06091865 · EU 2022-502785-25-00 - Phase 2/3Taking peopleA Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- Where
- Seoul
- Age
- 18 years and over
- People
- 290 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT05139017 · EU 2022-502646-27-00 - Phase 2Taking peopleStudy of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
- Where
- Busan, Daegu, Gyeongsangnam-do, Incheon, Jeonju, Seogu, Seoul, Suwon, Ulsan
- Age
- 65 years to 99 years
- People
- 80 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05952024 - Phase 1/2Taking peopleSubstudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Where
- Seoul
- Age
- 6 months to 25 years
- People
- 90 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00 - Phase 2Taking peopleConsolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Where
- Goyang-si, Hwasun, Seogu, Seoul, Suwon
- Age
- 18 years and over
- People
- 250 worldwide
- Run by
- Allogene Therapeutics
See details and how to joinNCT06500273 - Phase 1Taking peopleA Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- Where
- Daejeon, Seongnam, Seoul
- Age
- 18 years and over
- People
- 453 worldwide
- Run by
- Pfizer
See details and how to joinNCT03460977 · EU 2023-509179-18-00 - Phase 1/2Taking peopleA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Where
- GangnamGu, SeochoGu, SeodaemunGu, Seogu, Seoul, SongpaGu
- Age
- 18 years and over
- People
- 689 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00 - Phase 1/2Taking peopleA Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Where
- Daegu, Goyang-si, Incheon, Seoul
- Age
- 18 years and over
- People
- 300 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04104776 · EU 2023-508002-20-00 - No phaseTaking peopleLong-term Follow up Local Registry Study of Kymriah in South Korea
- Where
- Bundang Gu, Busan, Gyeonggi-do, Incheon, Jeollanam, Seongnam-si, Seoul, Ulsan
- Age
- 0 years to 100 years
- People
- 500
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06785818 - Phase 1/2Taking peopleStudy of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients
- Where
- Seoul
- Age
- 19 years and over
- People
- 91
- Run by
- Curocell Inc.
See details and how to joinNCT04836507 - Phase 2Taking peopleStudy of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.
- Where
- Seoul
- Age
- 19 years and over
- People
- 30
- Run by
- Kim, Seok Jin
See details and how to joinNCT04627753 - Phase 1/2Taking peopleStudy of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients
- Where
- Seoul
- Age
- 19 years and over
- People
- 98
- Run by
- TICAROS Co., Ltd.
See details and how to joinNCT07473167 - Phase 2Taking peopleAnbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma
- Where
- Seoul
- Age
- 19 years and over
- People
- 12
- Run by
- Hyungwoo Cho
See details and how to joinNCT07062627 - Phase 1/2Not yet taking people in South KoreaGolcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Where
- Seoul
- Age
- 19 years and over
- People
- 20
- Run by
- Seoul National University Hospital
See details and how to joinNCT07269639 - No phaseTaking peopleImmunotherapy in Lymphoma
- Where
- Seoul
- Age
- 19 years to 74 years
- People
- 72
- Run by
- Sung-Soo Park
See details and how to joinNCT06796517 - Phase 1/2Taking peopleSafety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
- Where
- Goyang, Incheon, Seoul
- Age
- 18 years and over
- People
- 84 worldwide
- Run by
- Kartos Therapeutics, Inc.
See details and how to joinNCT04502394